Jin Mo Ahn

Jin Mo Ahn

Auto-generated profile, based on publicly available information

Jin Mo Ahn

Genome Research Center, GC Genome, Yongin, Korea

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2025 in Cancer Research
Verified
Journal Article
Closed access
TLTae-Rim Lee
Tae-Rim Lee
JAJin Mo Ahn
Jin Mo Ahn
JLJunnam Lee
Junnam Lee
DKDasom Kim
Dasom Kim
JPJuntae Park
Juntae Park
ECEun-Hae Cho
Eun-Hae Cho
Early detection of lung cancer is important for improving patient survival rates. Liquid biopsy using whole-genome sequencing of cell-free DNA (cfDNA) offers a promising avenue for lung cancer screening, providing a potential alternative or complementary approach to current screening modalities. Here, we aimed to develop and validate an approach by integrating fragment and genomic features of cfDNA to enhance lung cancer detection accuracy across diverse populations. Deep learning–based classifiers were trained using comprehensive cfDNA fragmentomic features from participants in multi-institutional studies, including a Korean discovery dataset (218 patients with lung cancer and 2,559 controls), a Korean validation dataset (111 patients with lung cancer and 1,136 controls), and an independent Caucasian validation cohort (50 patients with lung cancer and 50 controls). In the discovery dataset, classifiers using fragment end motif by size, a feature that captures both fragment end motif and size profiles, outperformed standalone fragment end motif and fragment size classifiers, achieving an area under the curve (AUC) of 0.917. The ensemble classifier integrating fragment end motif by size and genomic coverage achieved an improved performance, with an AUC of 0.937. This performance extended to the Korean validation dataset and demonstrated ethnic generalizability in the Caucasian validation cohort. Overall, the development of a deep learning–based classifier integrating cfDNA fragmentomic and genomic features in this study highlights the potential for accurate lung cancer detection across diverse populations. Significance: Evaluating fragment-based features and genomic coverage in cell-free DNA offers an accurate lung cancer screening method, promising improvements in early cancer detection and addressing challenges associated with current screening methods.

19 November 2025 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
SHSeung Wook Hong
Seung Wook Hong
JPJuntae Park
Juntae Park
JLJunnam Lee
Junnam Lee
JAJin Mo Ahn
Jin Mo Ahn
DKDasom Kim
Dasom Kim
JBJeong-Sik Byeon
Jeong-Sik Byeon
INTRODUCTION: Fragmentomic analysis of blood-derived cell-free DNA (cfDNA) has emerged as a promising approach for cancer screening. We aimed to develop a novel cfDNA-based blood test and evaluate its diagnostic performance for colorectal cancer (CRC) and advanced adenoma (AA). METHODS: In this prospective case-control study, 1,677 participants were enrolled: 1,267 with normal colonoscopy, 302 with CRC, and 108 with AA. Participants were randomly assigned to either a development cohort (n = 1,250) or a validation cohort (n = 427). Whole-genome sequencing of cfDNA was performed to extract fragmentomic features, including end motifs, fragment lengths, and genome-wide coverage. A diagnostic model was developed using the Residual Enrichment From Independent Normal Ensemble method, and its performance was assessed in the validation cohort. RESULTS: In the validation cohort, the sensitivities for CRC and AA were 90.4% (95% CI, 82.2–97.3) and 58.3% (95% CI, 48.1–67.6), respectively. Overall accuracy for advanced neoplasia was 84.8% (95% CI, 81.1–87.8), and specificity in individuals with normal colonoscopy was 94.7% (95% CI, 91.2–96.9). The areas under the receiver operating characteristic curve were 0.978 for CRC and 0.862 for AA. Sensitivities by CRC stage were 84.2% (stage I), 85.0% (stage II), 94.4% (stage III), and 100.0% (stage IV). Diagnostic performance was consistent across CRC locations (left vs right colon), age of patients with CRC (<60 vs ≥60), and AA locations. DISCUSSION: This cfDNA-based blood test demonstrated high diagnostic accuracy for CRC and acceptable performance for AA. Its consistent performance across clinical subgroups suggests its potential as an effective noninvasive CRC screening tool.

31 December 2017 in Genomics & Informatics
Verified
Journal Article
Open access
PDF file
TLTae-Rim Lee
Tae-Rim Lee
JAJin Mo Ahn
Jin Mo Ahn
GKGyuhee Kim
Gyuhee Kim
SKSangsoo Kim
Sangsoo Kim
Next-generation sequencing (NGS) technology has become a trend in the genomics research area. There are many software programs and automated pipelines to analyze NGS data, which can ease the pain for traditional scientists who are not familiar with computer programming. However, downstream analyses, such as finding differentially expressed genes or visualizing linkage disequilibrium maps and genome-wide association study (GWAS) data, still remain a challenge. Here, we introduce a dockerized web application written in R using the Shiny platform to visualize pre-analyzed RNA sequencing and GWAS data. In addition, we have integrated a genome browser based on the JBrowse platform and an automated intermediate parsing process required for custom track construction, so that users can easily build and navigate their personal genome tracks with in-house datasets. This application will help scientists perform series of downstream analyses and obtain a more integrative understanding about various types of genomic data by interactively visualizing them with customizable options.

2 May 2025
Verified
Other
Open access
PDF file
TLTae-Rim Lee
Tae-Rim Lee
JAJin Mo Ahn
Jin Mo Ahn
JLJunnam Lee
Junnam Lee
DKDasom Kim
Dasom Kim
JPJuntae Park
Juntae Park
ECEun-Hae Cho
Eun-Hae Cho
Experimental Batch Effect on FEMS Feature Before and After Bias Correction.

2 May 2025
Verified
Other
Open access
TLTae-Rim Lee
Tae-Rim Lee
JAJin Mo Ahn
Jin Mo Ahn
JLJunnam Lee
Junnam Lee
DKDasom Kim
Dasom Kim
JPJuntae Park
Juntae Park
ECEun-Hae Cho
Eun-Hae Cho
Supplementary Table S5. The cancer prediction scores calculated by each classifier in the Korean, and Caucasian datset.

2 May 2025
Verified
Other
Open access
PDF file
TLTae-Rim Lee
Tae-Rim Lee
JAJin Mo Ahn
Jin Mo Ahn
JLJunnam Lee
Junnam Lee
DKDasom Kim
Dasom Kim
JPJuntae Park
Juntae Park
ECEun-Hae Cho
Eun-Hae Cho
Distribution of Cancer Prediction Score by Pathologic Type.